MAPT and Alzheimer disease: Several fluid biomarkers, including the measurement of total tau (t-tau), p-tau and β-amyloid (Aβ) in cerebrospinal fluid (CSF) or plasma, have shown promise in the diagnosis and early detection of AD [8-11].